The observed induction of CYP3A4 by sitagliptin could be attributed to sitagliptin’s anti-inflammatory and hepatoprotective effects, thereby inhibiting the cytokine-induced suppression of CYP3A4 that is often observed in hepatic inflammation and preneoplasia. This evidence concerns the gene CYP3A4 and inflammation.